Intra-Cellular to raise $115 million, move to NASDAQ

Intra-Cellular Therapies Inc. (OTCQB:ITCI) said it plans to raise up to $115 million in a follow-on and move its listing to NASDAQ. Leerink and Cowen are underwriters. Intra-Cellular began trading on OTCQB in December after completing a reverse merger with a public shell company. Next half, the company plans to start a Phase III trial of ITI-007 to treat schizophrenia. The compound is a dual serotonin (5-HT2A) receptor antagonist and dopamine receptor phosphoprotein modulator (DPPM) (see BioCentury Extra, Dec. 9, 2013). ...